Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC)

Shares of ChromaDex Corporation (NASDAQ:CDXC) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1 year consensus target price of $6.50 for the company, according to Zacks. Zacks has also assigned ChromaDex Corporation an industry rank of 111 out of 265 based on the ratings given to related companies.

Several brokerages recently weighed in on CDXC. Ladenburg Thalmann Financial Services began coverage on ChromaDex Corporation in a research note on Monday, September 25th. They issued a “buy” rating and a $7.00 price target on the stock. ValuEngine raised ChromaDex Corporation from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of ChromaDex Corporation in a research note on Monday, October 2nd. Finally, Zacks Investment Research cut ChromaDex Corporation from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 15th.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/11/21/analysts-set-6-50-target-price-for-chromadex-corporation-cdxc.html.

In related news, major shareholder River Ventures Ltd Champion bought 731,707 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were purchased at an average cost of $4.10 per share, with a total value of $2,999,998.70. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 11.59% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CDXC. Bank of Montreal Can purchased a new stake in shares of ChromaDex Corporation in the second quarter worth $168,000. LMR Partners LLP bought a new position in shares of ChromaDex Corporation during the second quarter valued at $347,000. Goldman Sachs Group Inc. lifted its holdings in shares of ChromaDex Corporation by 870.6% during the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock valued at $698,000 after purchasing an additional 163,817 shares in the last quarter. Thompson Davis & CO. Inc. bought a new position in shares of ChromaDex Corporation during the third quarter valued at $128,000. Finally, Granite Investment Partners LLC lifted its holdings in shares of ChromaDex Corporation by 5.7% during the third quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock valued at $1,076,000 after purchasing an additional 13,599 shares in the last quarter. 7.63% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ChromaDex Corporation (NASDAQ CDXC) traded up $0.13 during mid-day trading on Tuesday, reaching $6.63. The company had a trading volume of 543,700 shares, compared to its average volume of 304,292. ChromaDex Corporation has a 12 month low of $2.25 and a 12 month high of $7.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.12 and a current ratio of 5.03.

About ChromaDex Corporation

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Get a free copy of the Zacks research report on ChromaDex Corporation (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply